This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (71)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Alzheimer Disease  • Cerebrovascular Disease  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Christiane Reitz, MD; Ming-Xin Tang, PhD; Jose Luchsinger, MD; Richard Mayeux, MD

Arch Neurol. 2004;61:705-714.

Background  The relation between plasma lipid levels and Alzheimer disease (AD) and vascular dementia (VaD), and the impact of drugs to lower lipid levels remains unclear.

Objective  To investigate the relation between plasma lipid levels and the risk of AD and VaD and the impact of drugs to lower lipid levels on this relationship.

Design and Setting  Cross-sectional and prospective community-based cohort studies.

Participants  Random sample of 4316 Medicare recipients, 65 years and older, residing in northern Manhattan, NY.

Main Outcome Measures  Vascular dementia and AD according to standard criteria.

Results  Elevated levels of non–high-density lipoprotein (HDL-C) and low-density lipoprotein cholesterol (LDL-C) and decreased levels of HDL-C were weak risk factors for VaD in either cross-sectional or prospective analyses. Higher levels of total cholesterol were associated with a decreased risk of incident AD after adjustment for demographics, apolipoprotein E genotype, and cardiovascular risk factors. Treatment with drugs to lower lipid levels did not change the disease risk of either disorder.

Conclusions  We found a weak relation between non–HDL-C, LDL-C, and HDL-C levels and the risk of VaD. Lipid levels and the use of agents to lower them do not seem to be associated with the risk of AD.

From the Gertrude H. Sergievsky Center (Drs Reitz, Tang, Luchsinger, and Mayeux), the Taub Institute for Research on Alzheimer's Disease and the Aging Brain (Drs Luchsinger and Mayeux), the Departments of Medicine (Dr Luchsinger), Neurology (Dr Mayeux), and Psychiatry (Dr Mayeux), and the Departments of Biostatistics (Dr Tang) and Epidemiology (Dr Mayeux) in the Mailman School of Public Health, Columbia University College of Physicians and Surgeons, New York, NY.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effect of Dietary Unsaturated Fatty Acids on Senile Amyloidosis in Senescence-Accelerated Mice
Umezawa et al.
J Gerontol A Biol Sci Med Sci 2009;64A:646-652.
ABSTRACT | FULL TEXT  

Contribution of Vascular Risk Factors to the Progression in Alzheimer Disease
Helzner et al.
Arch Neurol 2009;66:343-348.
ABSTRACT | FULL TEXT  

Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study
Haag et al.
J. Neurol. Neurosurg. Psychiatry 2009;80:13-17.
ABSTRACT | FULL TEXT  

Metabolic Syndrome and Risk for Incident Alzheimer's Disease or Vascular Dementia: The Three-City Study
Raffaitin et al.
Diabetes Care 2009;32:169-174.
ABSTRACT | FULL TEXT  

A 60-Year-Old Woman With Mild Memory Impairment: Review of Mild Cognitive Impairment
Ellison
JAMA 2008;300:1566-1574.
ABSTRACT | FULL TEXT  

Low HDL Cholesterol Is a Risk Factor for Deficit and Decline in Memory in Midlife: The Whitehall II Study
Singh-Manoux et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:1556-1562.
ABSTRACT | FULL TEXT  

Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study
Cramer et al.
Neurology 2008;71:344-350.
ABSTRACT | FULL TEXT  

Baseline Serum Cholesterol Is Selectively Associated With Motor Speed and Not Rates of Cognitive Decline: The Women's Health and Aging Study II
Mielke et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2008;63:619-624.
ABSTRACT | FULL TEXT  

Relation of plasma lipids to all-cause mortality in Caucasian, African-American and Hispanic elders
Akerblom et al.
Age Ageing 2008;37:207-213.
ABSTRACT | FULL TEXT  

Characterization of the Lipid Profile in Dementia and Depression in the Elderly
Dimopoulos et al.
J Geriatr Psychiatry Neurol 2007;20:138-144.
ABSTRACT  

The Relation between Apolipoprotein A-I and Dementia: The Honolulu-Asia Aging Study
Saczynski et al.
Am J Epidemiol 2007;165:985-992.
ABSTRACT | FULL TEXT  

Invited Commentary: Lipoproteins and Dementia--Is It the Apolipoprotein A-I?
Scarmeas
Am J Epidemiol 2007;165:993-997.
ABSTRACT | FULL TEXT  

Serum cholesterol changes after midlife and late-life cognition: Twenty-one-year follow-up study
Solomon et al.
Neurology 2007;68:751-756.
ABSTRACT | FULL TEXT  

Twenty-six-Year Change in Total Cholesterol Levels and Incident Dementia: The Honolulu-Asia Aging Study
Stewart et al.
Arch Neurol 2007;64:103-107.
ABSTRACT | FULL TEXT  

Education and rates of cognitive decline in incident Alzheimer's disease.
Scarmeas et al.
J. Neurol. Neurosurg. Psychiatry 2006;77:308-316.
ABSTRACT | FULL TEXT  

Serum cholesterol and risk of Alzheimer disease: A community-based cohort study
Li et al.
Neurology 2005;65:1045-1050.
ABSTRACT | FULL TEXT  

Aggregation of vascular risk factors and risk of incident Alzheimer disease
Luchsinger et al.
Neurology 2005;65:545-551.
ABSTRACT | FULL TEXT  

High total cholesterol levels in late life associated with a reduced risk of dementia
Mielke et al.
Neurology 2005;64:1689-1695.
ABSTRACT | FULL TEXT  

APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: The Three-City Study
Dufouil et al.
Neurology 2005;64:1531-1538.
ABSTRACT | FULL TEXT